The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...

A 63-year-old woman with a 20-year history of hidradenitis suppurativa, classified as Hurley Stage III (a disease-specific staging system); a 12 pack-year smoking history; pyoderma gangrenosum; and ...

On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

Camrelizumab plus famitinib significantly improved PFS and OS compared to platinum-based chemotherapy in recurrent/metastatic cervical cancer. The trial reported a median PFS of 11.1 months for the ...

This Melanoma Awareness Month, don’t wait. Skin cancer doesn’t slow down, and neither should you. Keep an eye on your skin but know that the most effective way to catch changes early is with regular ...

Mohs microscopic surgery and image-guided superficial radiation therapy (IG-SRT) demonstrate high local cure rates in the management of non-melanoma skin cancer.

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...